ARROWHEAD PHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
ARROWHEAD PHARMACEUTICALS INC. - More news...
ARROWHEAD PHARMACEUTICALS INC. - More news...
- Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
- Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
- Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
- Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
- Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
- Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
- Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
- Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
- Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
- Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
- Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
- Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
- Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
- Thinking about buying stock in XPO, Virios Therapeutics, Arrowhead Pharmaceuticals, Petros Pharmaceuticals, or Citius Pharmaceuticals?
- Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
- Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
- Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics
- First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
- Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
- Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
- Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
- Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
